Patrick Dallemagne,Christophe Rochais
Patrick Dallemagne
Patentability challenges associated with emerging pharmaceutical technologies [0.03%]
与新兴医药技术相关的专利挑战性问题
Srishti Aggarwal,Amrish Chandra
Srishti Aggarwal
According to the recent patent filing trends, it has been observed that certain pharmaceutical technologies are more popular than others and are commonly referred to as emerging technologies. The emerging technologies in the pharmaceutical ...
Hermann Am Mucke
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
Cannabinoid receptor type 2 ligands: an analysis of granted patents since 2010 [0.03%]
专利分析：2010年后大麻素受体2型配体相关授权专利盘点
Benjamin Brennecke,Thais Gazzi,Kenneth Atz et al.
Benjamin Brennecke et al.
The G-protein-coupled cannabinoid receptor type 2 (CB2R) is a key element of the endocannabinoid (EC) system. EC/CB2R signaling has significant therapeutic potential in major pathologies affecting humans such as allergies, neurodegenerative...
Contemporary approaches to treat Naegleria fowleri: a patent overview [0.03%]
治疗Naegleria fowleri的当代方法：专利概览
Ruqaiyyah Siddiqui,Naveed A Khan
Ruqaiyyah Siddiqui
Slobodan M Janković,Nenad Marković,Tanja Luković
Slobodan M Janković
Focal epilepsy is one of the most frequent specific type of epilepsies, with 30% treatment-resistant patients. There are several directions researchers can follow to improve existing treatment of focal epilepsy: synthesis of new compounds w...
Hermann Am Mucke
Hermann Am Mucke
A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.
Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis [0.03%]
骨质疏松症和抗癌药物的近期研发动向：基于专利分析的结果
Hai-Long Zhang,Yiqian Li
Hai-Long Zhang
Osteoporosis and cancer are becoming a major public health problem. Some studies have shown that osteoporosis drugs may have anti-cancer effects. To better understand the relationship between drugs for osteoporosis and antineoplastic agents...
Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody [0.03%]
一种用于治疗实体瘤的双特异抗PDL-1/ICOS抗体的治疗方法
Martin Perez-Santos,Maricruz Anaya-Ruiz,Gabriela Sanchez-Esgua et al.
Martin Perez-Santos et al.
PD-L1 and ICOS are immune control points in cancer and their presence in cancer tends to have a poor prognosis. WO2019122882 patent describes a bispecific antibody that targets PDL-1/ICOS with the potential application of cancer treatment. ...